These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15790082)

  • 1. Vioxx and Merck: a preventable situation?
    Torg J
    Orthopedics; 2005 Mar; 28(3):248, 250. PubMed ID: 15790082
    [No Abstract]   [Full Text] [Related]  

  • 2. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 3. [Really only Vioxx?].
    Heinzl S
    Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
    [No Abstract]   [Full Text] [Related]  

  • 4. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 5. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
    MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091
    [No Abstract]   [Full Text] [Related]  

  • 6. Discontinuation of Vioxx.
    Nutt DJ
    Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
    [No Abstract]   [Full Text] [Related]  

  • 7. Lessons to be learned from the Vioxx debacle.
    Beller GA
    J Nucl Cardiol; 2005; 12(1):1-2. PubMed ID: 15682357
    [No Abstract]   [Full Text] [Related]  

  • 8. The lessons of Vioxx--drug safety and sales.
    Waxman HA
    N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
    [No Abstract]   [Full Text] [Related]  

  • 9. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
    Cahana A; Mauron A
    J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707
    [No Abstract]   [Full Text] [Related]  

  • 10. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 11. Vioxx, the implosion of Merck, and aftershocks at the FDA.
    Horton R
    Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
    [No Abstract]   [Full Text] [Related]  

  • 12. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing risks and benefits in pain medicine: wither Vioxx.
    Gallagher RM
    Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
    [No Abstract]   [Full Text] [Related]  

  • 14. Was Vioxx really that dangerous?
    Park A
    Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
    [No Abstract]   [Full Text] [Related]  

  • 15. The withdrawal of rofecoxib.
    Arellano FM
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
    [No Abstract]   [Full Text] [Related]  

  • 16. [Selective COX-2 inhibitors--strong medicine for pain].
    MMW Fortschr Med; 2004 Apr; 146(17):56-7. PubMed ID: 15224910
    [No Abstract]   [Full Text] [Related]  

  • 17. Merck withdraws Vioxx; FDA issues public health advisory.
    FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
    [No Abstract]   [Full Text] [Related]  

  • 18. Merck VIOXX "warning" is questioned.
    Allen TS; Henderson JH
    Tex Med; 2005 May; 101(5):5-6. PubMed ID: 15948521
    [No Abstract]   [Full Text] [Related]  

  • 19. Discontinuation of Vioxx.
    Garattini S; Bertelé V
    Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
    [No Abstract]   [Full Text] [Related]  

  • 20. The changing landscape for COX-2 inhibitors: a summary of recent events.
    Mamdani M
    Healthc Q; 2005; 8(2):24, 26. PubMed ID: 15828561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.